Margetuximab Approved for HER2+ Metastatic Breast Cancer ...Middle East

A new monoclonal antibody targeting HER2 in breast cancer, margetuximab-cmkb, has shown superiority over trastuzumab in improving progression-free survival in heavily pretreated women. FDA Approvals

Hence then, the article about margetuximab approved for her2 metastatic breast cancer was published today ( Friday 18/12/2020 - 01:00 AM ) and is available on Medscape ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Margetuximab Approved for HER2+ Metastatic Breast Cancer )

Also on site :

• U.S. military launches 10th straight night of airstrikes on Iran as Houthi allies threaten Red Sea, but glimmers of hope appear on diplomatic front
• T.J. Maxx's Beautiful Linen Dining Chair Sets Has Shoppers Racing to Buy Them Before They're Gone for Good
• 1928 Beach Legend, Named Among Most 'Historic Hotels of America,' Is Still a Vintage Hotspot Nearly 10 Decades Later